Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB–IV NSCLC (LCDigital-IO Study): a multicenter retrospective study

Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB–IV NSCLC (LCDigital-IO Study): a multicenter retrospective study

Background The predictive efficacy of current biomarker of immune checkpoint inhibitors (ICIs) is not sufficient. This study investigated the causality between radiomic biomarkers and immunotherapy response status in patients with stage IB–IV non-small cell lung cancer (NSCLC), including its biologi...

Full description

Bibliographic Details
Main Authors: Bin Xu, Lan Liu, Shaowei Wu, Guangyi Wang, Guibin Qiao, Weijie Zhan, Daipeng Xie, Lintong Yao, Henian Yao, Guoqing Liao, Luyu Huang, Yubo Zhou, Peimeng You, Zekai Huang, Qiaxuan Li, Siyun Wang, Dong-Kun Zhang, Lawrence Wing-Chi Chan, Michael Lanuti, Haiyu Zhou
Format: Article
Language:English
Published: BMJ Publishing Group 2023-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/10/e007369.full

Internet

https://jitc.bmj.com/content/11/10/e007369.full

Similar Items